Bogart Wealth LLC grew its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 5.9% in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 387,779 shares of the biopharmaceutical company's stock after buying an additional 21,526 shares during the quarter. Bogart Wealth LLC's holdings in Pfizer were worth $9,826,000 as of its most recent filing with the SEC.
Other large investors also recently bought and sold shares of the company. Clarity Asset Management Inc. purchased a new position in shares of Pfizer in the 4th quarter valued at about $27,000. Gould Capital LLC increased its holdings in shares of Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 493 shares in the last quarter. North Capital Inc. purchased a new position in shares of Pfizer in the 1st quarter valued at about $28,000. Bernard Wealth Management Corp. purchased a new position in Pfizer during the 4th quarter valued at about $30,000. Finally, Curio Wealth LLC purchased a new position in Pfizer during the 4th quarter valued at about $32,000. Hedge funds and other institutional investors own 68.36% of the company's stock.
Pfizer Trading Down 0.5%
PFE opened at $25.65 on Monday. The firm has a market capitalization of $145.83 billion, a P/E ratio of 18.59, a P/E/G ratio of 0.93 and a beta of 0.58. The firm's 50 day moving average is $23.89 and its 200-day moving average is $24.78. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $31.54. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64.
Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. The business had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The business's revenue was down 7.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.82 earnings per share. Analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.
Pfizer Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.71%. Pfizer's dividend payout ratio (DPR) is presently 124.64%.
Analyst Ratings Changes
Several equities analysts have weighed in on PFE shares. Jefferies Financial Group raised their target price on shares of Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a report on Wednesday, May 21st. Morgan Stanley raised their target price on shares of Pfizer from $31.00 to $32.00 and gave the company an "equal weight" rating in a report on Wednesday, April 30th. Bank of America raised their target price on shares of Pfizer from $26.00 to $27.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. UBS Group raised their price target on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. Finally, Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $28.55.
Read Our Latest Stock Analysis on PFE
Pfizer Company Profile
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Featured Stories
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
